[go: up one dir, main page]

WO2010089617A3 - Préparations pharmaceutiques transdermiques - Google Patents

Préparations pharmaceutiques transdermiques Download PDF

Info

Publication number
WO2010089617A3
WO2010089617A3 PCT/HU2010/000015 HU2010000015W WO2010089617A3 WO 2010089617 A3 WO2010089617 A3 WO 2010089617A3 HU 2010000015 W HU2010000015 W HU 2010000015W WO 2010089617 A3 WO2010089617 A3 WO 2010089617A3
Authority
WO
WIPO (PCT)
Prior art keywords
transdermal pharmaceutical
pharmaceutical preparations
bioavailability
dispersed
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2010/000015
Other languages
English (en)
Other versions
WO2010089617A2 (fr
Inventor
Endre Mikulásik
Patrik Fazekas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2010800111061A priority Critical patent/CN102573793A/zh
Priority to UAA201110091A priority patent/UA107563C2/uk
Priority to CA2751633A priority patent/CA2751633A1/fr
Priority to EP10707660A priority patent/EP2393479A2/fr
Priority to MX2011008213A priority patent/MX2011008213A/es
Priority to JP2011548789A priority patent/JP2012517414A/ja
Priority to EA201190134A priority patent/EA023502B1/ru
Priority to US13/148,219 priority patent/US20120024743A1/en
Priority to AU2010212158A priority patent/AU2010212158A1/en
Application filed by Egis Pharmaceuticals PLC filed Critical Egis Pharmaceuticals PLC
Priority to NZ594618A priority patent/NZ594618A/en
Priority to BRPI1005433A priority patent/BRPI1005433A2/pt
Publication of WO2010089617A2 publication Critical patent/WO2010089617A2/fr
Publication of WO2010089617A3 publication Critical patent/WO2010089617A3/fr
Priority to ZA2011/05662A priority patent/ZA201105662B/en
Priority to IL214402A priority patent/IL214402A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)

Abstract

La présente invention concerne une préparation pharmaceutique transdermique semi-solide à stabilité et biodisponibilité renforcées. En l'occurrence, les particules sont enduites d'un composant volatil à base d'huile silicone, la suspension ainsi obtenue constituant une base de gel ou de crème.
PCT/HU2010/000015 2007-07-10 2010-02-05 Préparations pharmaceutiques transdermiques Ceased WO2010089617A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU2010212158A AU2010212158A1 (en) 2007-07-10 2010-02-05 Transdermal pharmaceutical preparations
CA2751633A CA2751633A1 (fr) 2009-02-06 2010-02-05 Preparations pharmaceutiques transdermiques
EP10707660A EP2393479A2 (fr) 2009-02-06 2010-02-05 Préparations pharmaceutiques transdermiques
MX2011008213A MX2011008213A (es) 2009-02-06 2010-02-05 Preparaciones farmaceuticas transdermicas.
JP2011548789A JP2012517414A (ja) 2009-02-06 2010-02-05 経皮医薬組成物
EA201190134A EA023502B1 (ru) 2009-02-06 2010-02-05 Трансдермальная фармацевтическая композиция (варианты)
US13/148,219 US20120024743A1 (en) 2009-02-06 2010-02-05 Transdermal pharmaceutical preparations
CN2010800111061A CN102573793A (zh) 2009-02-06 2010-02-05 透皮药物制剂
NZ594618A NZ594618A (en) 2009-02-06 2010-02-05 Transdermal pharmaceutical preparations
UAA201110091A UA107563C2 (uk) 2009-02-06 2010-02-05 Фармацевтичний препарат для трансдермального застосування
BRPI1005433A BRPI1005433A2 (pt) 2009-02-06 2010-02-05 preparações farmacêuticas transdérmicas
ZA2011/05662A ZA201105662B (en) 2009-02-06 2011-08-01 Transdermal pharmaceutical preparations
IL214402A IL214402A0 (en) 2009-02-06 2011-08-02 Transdermal pharmaceutical preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0900072A HUP0900072A2 (hu) 2009-02-06 2009-02-06 Transzdermális gyógyszerkészítmények
HUP0900072 2009-02-06

Publications (2)

Publication Number Publication Date
WO2010089617A2 WO2010089617A2 (fr) 2010-08-12
WO2010089617A3 true WO2010089617A3 (fr) 2011-06-16

Family

ID=89988766

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2010/000015 Ceased WO2010089617A2 (fr) 2007-07-10 2010-02-05 Préparations pharmaceutiques transdermiques

Country Status (18)

Country Link
US (1) US20120024743A1 (fr)
EP (1) EP2393479A2 (fr)
JP (1) JP2012517414A (fr)
KR (1) KR20110120304A (fr)
CN (2) CN103349643A (fr)
AU (1) AU2010212158A1 (fr)
BR (1) BRPI1005433A2 (fr)
CA (1) CA2751633A1 (fr)
CL (1) CL2011001875A1 (fr)
EA (1) EA023502B1 (fr)
HU (1) HUP0900072A2 (fr)
IL (1) IL214402A0 (fr)
MX (1) MX2011008213A (fr)
NZ (1) NZ594618A (fr)
PE (1) PE20120584A1 (fr)
UA (1) UA107563C2 (fr)
WO (1) WO2010089617A2 (fr)
ZA (1) ZA201105662B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274165B2 (en) 2017-02-28 2022-03-15 Oji Holdings Corporation Pentosan polysulfate, pharmaceutical composition, and anticoagulant
US11278485B2 (en) 2017-05-31 2022-03-22 Oji Holdings Corporation Moisturizing topical preparation
US11286272B2 (en) 2016-08-31 2022-03-29 Oji Holdings Corporation Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide
US11312790B2 (en) 2016-08-31 2022-04-26 Oji Holdings Corporation Production method for pentosan polysulfate
US11344570B2 (en) 2017-12-20 2022-05-31 Oji Holdings Corporation Pentosan polysulfate and medicine containing pentosan polysulfate
US11390693B2 (en) 2017-09-12 2022-07-19 Oji Holdings Corporation Pentosan polysulfate and method for producing pentosan polysulfate

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170065533A1 (en) * 2011-01-24 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles for dermal and systemic delivery of drugs
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045935B2 (en) * 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
JP5630679B1 (ja) * 2013-09-08 2014-11-26 株式会社Ｅ・テック 揮発性消毒剤、揮発性消毒剤の製造方法
KR20170003527A (ko) * 2014-02-24 2017-01-09 유리젠 파마슈티컬스, 인코포레이티드 경구 투여용 펜토산 폴리설페이트 염의 조성물
RU2704623C1 (ru) * 2018-12-07 2019-10-30 Общество с ограниченной ответственностью "Научно-производственное объединение "Ликом" Перевязочное средство на биополимерной основе
WO2022007917A1 (fr) * 2020-07-10 2022-01-13 江苏恒瑞医药股份有限公司 Préparation transdermique contenant un principe actif de médicament anesthésique et sa méthode de préparation
CN115475224B (zh) * 2022-08-31 2023-11-28 中国人民解放军空军特色医学中心 一种用于治疗冻疮的药膏及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287322A2 (fr) * 1987-04-14 1988-10-19 Richardson-Vicks, Inc. Emulsion pharmaceutique stable du type eau-dans-huile
EP0639372A1 (fr) * 1993-08-18 1995-02-22 Laboratoires Cilag Dispositif de distribution d'une substance thérapeutique ou cosmétique dont le véhicule inerte est un polydiorganosiloxane volatil, et composition destinée à être utilisée dans le dispositif
WO2006138035A1 (fr) * 2005-06-13 2006-12-28 Dow Corning Corporation Vehicule pour l'administration d'agents pharmaceutiques solubles lipidiques topiques
WO2009007764A2 (fr) * 2007-07-10 2009-01-15 Egis Gyógyszergyár Nyilvánosan Müködö Préparations pharmaceutiques contenant des silicones hautement volatiles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1141094B (it) 1979-12-03 1986-10-01 Gen Electric Emulsioni di siliconi volantili e acqua e loro metodo di preparazione ed uso
DE3010572C2 (de) 1980-03-19 1982-05-06 Süess, Hans R., Dr., Starrkirch Hautpflege- und Hautschutzpräparate
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
US5336692A (en) 1990-06-28 1994-08-09 Medicis Pharmaceutical Corporation Ointment base and method of use
DE19837850C1 (de) 1998-08-20 2000-01-05 Wacker Chemie Gmbh Mischungen flüchtiger linearer Siloxane, Verfahren zu ihrer Herstellung sowie diese enthaltenden kosmetischen Formulierungen
IT1302275B1 (it) 1998-09-25 2000-09-05 Giorgio Panin Formulazione di gel idrofobo a base di vitamina e acetato perapplicazione topica.
JP4174595B2 (ja) 2001-11-13 2008-11-05 モーメンテイブ・パーフオーマンス・マテリアルズ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 蒸発可能な担体としてのシロキサンの使用
MXPA06005587A (es) 2003-11-21 2006-08-11 Galderma Res & Dev Composicion rociable para administracion de derivados de vitamina d.
GB0506139D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
EP1928415A2 (fr) * 2005-08-13 2008-06-11 Collegium Pharmaceutical, Inc. Administration topique a l'aide d'un fluide porteur

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287322A2 (fr) * 1987-04-14 1988-10-19 Richardson-Vicks, Inc. Emulsion pharmaceutique stable du type eau-dans-huile
EP0639372A1 (fr) * 1993-08-18 1995-02-22 Laboratoires Cilag Dispositif de distribution d'une substance thérapeutique ou cosmétique dont le véhicule inerte est un polydiorganosiloxane volatil, et composition destinée à être utilisée dans le dispositif
WO2006138035A1 (fr) * 2005-06-13 2006-12-28 Dow Corning Corporation Vehicule pour l'administration d'agents pharmaceutiques solubles lipidiques topiques
WO2009007764A2 (fr) * 2007-07-10 2009-01-15 Egis Gyógyszergyár Nyilvánosan Müködö Préparations pharmaceutiques contenant des silicones hautement volatiles

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11286272B2 (en) 2016-08-31 2022-03-29 Oji Holdings Corporation Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide
US11312790B2 (en) 2016-08-31 2022-04-26 Oji Holdings Corporation Production method for pentosan polysulfate
US11274165B2 (en) 2017-02-28 2022-03-15 Oji Holdings Corporation Pentosan polysulfate, pharmaceutical composition, and anticoagulant
US11278485B2 (en) 2017-05-31 2022-03-22 Oji Holdings Corporation Moisturizing topical preparation
US11390693B2 (en) 2017-09-12 2022-07-19 Oji Holdings Corporation Pentosan polysulfate and method for producing pentosan polysulfate
US11344570B2 (en) 2017-12-20 2022-05-31 Oji Holdings Corporation Pentosan polysulfate and medicine containing pentosan polysulfate

Also Published As

Publication number Publication date
CA2751633A1 (fr) 2010-08-12
CL2011001875A1 (es) 2012-07-13
IL214402A0 (en) 2011-09-27
KR20110120304A (ko) 2011-11-03
WO2010089617A2 (fr) 2010-08-12
CN102573793A (zh) 2012-07-11
CN103349643A (zh) 2013-10-16
US20120024743A1 (en) 2012-02-02
EP2393479A2 (fr) 2011-12-14
EA023502B1 (ru) 2016-06-30
HUP0900072A2 (hu) 2010-09-28
AU2010212158A1 (en) 2011-09-08
BRPI1005433A2 (pt) 2019-09-24
ZA201105662B (en) 2012-10-31
UA107563C2 (uk) 2015-01-26
HU0900072D0 (en) 2009-03-30
MX2011008213A (es) 2011-09-28
EA201190134A1 (ru) 2012-02-28
NZ594618A (en) 2014-01-31
JP2012517414A (ja) 2012-08-02
PE20120584A1 (es) 2012-05-23

Similar Documents

Publication Publication Date Title
WO2010089617A3 (fr) Préparations pharmaceutiques transdermiques
WO2015018380A3 (fr) Nanoparticules thérapeutiques et leurs procédés de préparation
WO2013177421A3 (fr) Compositions de nanoparticules d'albumine à revêtement lipidique ainsi que procédés de fabrication et procédé d'utilisation de celles-ci
WO2010013224A3 (fr) Nanoparticules de curcumine et leurs procédés de production
WO2010028015A3 (fr) Modulateurs 2-oxo-1,2-dihydro-quinoléines de la fonction immunitaire
WO2011130615A3 (fr) Synthèse de lacosamide
WO2010021607A3 (fr) Préparation pharmaceutique
WO2013126746A3 (fr) Nouveaux modulateurs et leurs procédés d'utilisation
WO2013185082A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2012174158A3 (fr) Administration de benzodiazépine
WO2010000877A3 (fr) Formulation à base de bisabolol et de [6]-paradol produisant un effet apaisant sur les irritations
WO2011135461A3 (fr) Compositions d'argile
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2013134534A3 (fr) Formes à l'état solide de cabazitaxel et procédés pour les préparer
EP2816034A3 (fr) Composés modulateurs d'une protéine CFTR mutante et leur utilisation pour le traitement de maladies associées à un dysfonctionnement de la protéine CFTR
EP3278799A4 (fr) Composition pharmaceutique de nanoparticules d'albumine et de docétaxel, procédé de préparation de ladite composition et son utilisation
WO2009007764A3 (fr) Préparations pharmaceutiques contenant des silicones hautement volatiles
WO2015061798A3 (fr) Compositions et procédés faisant appel à des organismes de type levures et à des extraits lipidiques de ceux-ci
WO2012049307A3 (fr) Nouveaux dérivés d'insuline à extrémité n modifiée
WO2009115084A3 (fr) Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
WO2009026257A8 (fr) Procédés et compositions pour contrôler la biodisponibilité de médicaments faiblement solubles
WO2011102668A3 (fr) Dérivés de colchicine ou leurs sels pharmaceutiquement acceptables, procédé pour la préparation desdits dérivés, et composition pharmaceutique comportant lesdits dérivés
TN2010000334A1 (en) Semisolid pharmaceutical formulations
WO2007009989A3 (fr) COMPOSITION COMPRENANT UNE DISPERSION LIPOSOMALE DE NANOPARTICULES DE SIO2 ET UN DERIVE D'ETHER DE GLUCANE A LIAISON ß-1,3
WO2007086911A3 (fr) Formulations nanoparticulaires stables

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080011106.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10707660

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 214402

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2011001875

Country of ref document: CL

Ref document number: 001443-2011

Country of ref document: PE

Ref document number: MX/A/2011/008213

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2011548789

Country of ref document: JP

Ref document number: 2751633

Country of ref document: CA

Ref document number: 12011501585

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: a201110091

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 594618

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2010212158

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 6360/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 201190134

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20117020176

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010707660

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: DZP2011000584

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2010212158

Country of ref document: AU

Date of ref document: 20100205

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13148219

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI1005433

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110805